Literature DB >> 12006644

Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions.

Louie Lamorte1, Isabelle Royal, Monica Naujokas, Morag Park.   

Abstract

Activation of the Met receptor tyrosine kinase through its ligand, hepatocyte growth factor (HGF), promotes an epithelial-mesenchymal transition and cell dispersal. However, little is known about the HGF-dependent signals that regulate these events. HGF stimulation of epithelial cell colonies leads to the enhanced recruitment of the CrkII and CrkL adapter proteins to Met-dependent signaling complexes. We provide evidence that signals involving CrkII and CrkL are required for the breakdown of adherens junctions, the spreading of epithelial colonies, and the formation of lamellipodia in response to HGF. The overexpression of a CrkI SH3 domain mutant blocks these HGF-dependent events. In addition, the overexpression of CrkII or CrkL promotes lamellipodia formation, loss of adherens junctions, cell spreading, and dispersal of colonies of breast cancer epithelial cells in the absence of HGF. Stable lines of epithelial cells overexpressing CrkII show enhanced activation of Rac1 and Rap1. The Crk-dependent breakdown of adherens junctions and cell spreading is inhibited by the expression of a dominant negative mutant of Rac1 but not Rap1. These findings provide evidence that Crk adapter proteins play a critical role in the breakdown of adherens junctions and the spreading of sheets of epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006644      PMCID: PMC111118          DOI: 10.1091/mbc.01-10-0477

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  61 in total

1.  A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein.

Authors:  L Lamorte; D M Kamikura; M Park
Journal:  Oncogene       Date:  2000-12-07       Impact factor: 9.867

Review 2.  Epithelial cell shape: cadherins and small GTPases.

Authors:  V Braga
Journal:  Exp Cell Res       Date:  2000-11-25       Impact factor: 3.905

Review 3.  Rap1 signalling: adhering to new models.

Authors:  J L Bos; J de Rooij; K A Reedquist
Journal:  Nat Rev Mol Cell Biol       Date:  2001-05       Impact factor: 94.444

Review 4.  Induction and regulation of epithelial-mesenchymal transitions.

Authors:  B Boyer; A M Vallés; N Edme
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

5.  Requirement for C3G-dependent Rap1 activation for cell adhesion and embryogenesis.

Authors:  Y Ohba; K Ikuta; A Ogura; J Matsuda; N Mochizuki; K Nagashima; K Kurokawa; B J Mayer; K Maki; J Miyazaki ; M Matsuda
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

6.  Activation of Rac1 by a Crk SH3-binding protein, DOCK180.

Authors:  E Kiyokawa; Y Hashimoto; S Kobayashi; H Sugimura; T Kurata; M Matsuda
Journal:  Genes Dev       Date:  1998-11-01       Impact factor: 11.361

7.  Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.

Authors:  B Hemmeryckx; A van Wijk; A Reichert; V Kaartinen; R de Jong; P K Pattengale; I Gonzalez-Gomez; J Groffen; N Heisterkamp
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

8.  RAC1 regulates adherens junctions through endocytosis of E-cadherin.

Authors:  N Akhtar; N A Hotchin
Journal:  Mol Biol Cell       Date:  2001-04       Impact factor: 4.138

Review 9.  The receptor tyrosine kinases: role in cancer progression.

Authors:  L Lamorte; M Park
Journal:  Surg Oncol Clin N Am       Date:  2001-04       Impact factor: 3.495

10.  Activation of ARF6 by ARNO stimulates epithelial cell migration through downstream activation of both Rac1 and phospholipase D.

Authors:  L C Santy; J E Casanova
Journal:  J Cell Biol       Date:  2001-07-30       Impact factor: 10.539

View more
  47 in total

1.  Apoptosis and Compensatory Proliferation Signaling Are Coupled by CrkI-Containing Microvesicles.

Authors:  Kajal H Gupta; Josef W Goldufsky; Stephen J Wood; Nicholas J Tardi; Gayathri S Moorthy; Douglas Z Gilbert; Janet P Zayas; Eunsil Hahm; Mehmet M Altintas; Jochen Reiser; Sasha H Shafikhani
Journal:  Dev Cell       Date:  2017-06-19       Impact factor: 12.270

2.  Membrane targeting of Grb2-associated binder-1 (Gab1) scaffolding protein through Src myristoylation sequence substitutes for Gab1 pleckstrin homology domain and switches an epidermal growth factor response to an invasive morphogenic program.

Authors:  Christiane R Maroun; Monica A Naujokas; Morag Park
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

3.  CrkII transgene induces atypical mammary gland development and tumorigenesis.

Authors:  Kelly E Fathers; Sonia Rodrigues; Dongmei Zuo; Indrani Vasudeva Murthy; Michael Hallett; Robert Cardiff; Morag Park
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

4.  Models of crk adaptor proteins in cancer.

Authors:  Emily S Bell; Morag Park
Journal:  Genes Cancer       Date:  2012-05

Review 5.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

6.  Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor.

Authors:  Grigorios N Paliouras; Monica A Naujokas; Morag Park
Journal:  Mol Cell Biol       Date:  2009-03-16       Impact factor: 4.272

7.  The adaptor protein CrkII regulates IGF-1-induced biological behaviors of pancreatic ductal adenocarcinoma.

Authors:  Rui Liu; Qing Wang; Guangying Xu; Kexin Li; Lingli Zhou; Baofeng Xu
Journal:  Tumour Biol       Date:  2015-08-07

8.  Focal adhesion components are essential for mammalian cell cytokinesis.

Authors:  Sasha H Shafikhani; Keith Mostov; Joanne Engel
Journal:  Cell Cycle       Date:  2008-09-25       Impact factor: 4.534

9.  Crk associates with a multimolecular Paxillin/GIT2/beta-PIX complex and promotes Rac-dependent relocalization of Paxillin to focal contacts.

Authors:  Louie Lamorte; Sonia Rodrigues; Veena Sangwan; Christopher E Turner; Morag Park
Journal:  Mol Biol Cell       Date:  2003-04-04       Impact factor: 4.138

10.  A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Authors:  Lainie P Martin; Michael Sill; Mark S Shahin; Matthew Powell; Paul DiSilvestro; Lisa M Landrum; Stephanie L Gaillard; Michael J Goodheart; James Hoffman; Russell J Schilder
Journal:  Gynecol Oncol       Date:  2013-12-18       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.